cardinal health glp-1 receptor agonist weight management diabetes treatments agonists cardinal health glp-1 receptor agonist

Neuronal failure in Alzheimers disease: a view through the oxidative stress looking-glass

Acknowledgements This work was supported by grants from the National Natural Science Foundation of China (81930019, 82341076) to Jin-Kui Yang

Schjoedt KJ, Rossing K, Juhl TR et al (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

When BMI and comorbidity thresholds are met for anti obesity pharmacotherapy, GLP-1 agonists are recommended as first line or preferred pharmacologic options because of superior weight loss efficacy and cardiometabolic benefit

GLP-1 RAs available in 2020 and their pharmacokinetic properties (Table 1) Table 1

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM)